Related Experiment Video

Updated: Jul 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy

Yajun Duan1, Junnian Zheng, Sufang Han

  • 1Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Science, Nankai University, Tianjin 300071, China.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|March 5, 2008
PubMed

Insights

Researchers developed a G250 antibody-Polyethylenimine (PEI) conjugate for targeted renal cell carcinoma (RCC) gene therapy. This conjugate significantly enhanced gene transfection in G250-positive RCC cells, showing promise for effective RCC treatment.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Oncology

Background:

  • Renal cell carcinoma (RCC) expresses the G250 tumor-associated antigen on over 90% of tumors.
  • Targeted gene delivery systems are crucial for effective RCC gene therapy.

Purpose of the Study:

  • To develop and characterize a G250 monoclonal antibody-Polyethylenimine (PEI) conjugate for targeted gene delivery in RCC.
  • To evaluate the targeting efficacy and transfection efficiency of the IgG-PEI conjugate in RCC cells.

Main Methods:

  • Preparation, purification, and characterization of G250 monoclonal antibody.
  • Chemical conjugation of G250 antibody to PEI to form the IgG-PEI conjugate.
  • Assessment of DNA complex formation, targeting effect, and transfection efficiency using cell lines (ketr 3, Hela, ACHN, HepG2, smooth muscle cells), Fluorescence Activated Cell Sorting (FACS), and luciferase assay.

Main Results:

  • The IgG-PEI conjugate formed nano-sized DNA complexes with narrow size distribution.
  • Transfection efficiency was 2-fold higher in G250-positive cells (ketr 3, Hela) compared to PEI alone.
  • Transfection efficiency was not affected in G250-negative cells.
  • Luciferase expression was significantly higher (15-fold and 61-fold) in ketr 3 cells compared to ACHN and smooth muscle cells, respectively.
  • Targeting effect and transfection efficiency were reduced in the presence of free G250 antibody, confirming specific targeting.

Conclusions:

  • The G250 antibody serves as an effective targeting ligand for gene delivery into RCC cells.
  • The developed IgG-PEI conjugate demonstrates significant potential for targeted RCC gene therapy applications.

More Related Videos

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.